NEW YORK (TheStreet) -- Shares of Vertex Pharmaceuticals (VRTX) - Get Report were down in early-afternoon trading on Wednesday after reporting 2016 third-quarter earnings and revenue that missed analysts' estimates.
After yesterday's market close, the Boston-based pharmaceutical company reported adjusted earnings of 16 cents per share, below analysts' estimates of 18 cents per share.
Revenue of $413.8 million fell short of analysts' estimates of $417.3 million.
On Vertex's earnings conference call, the company didn't express any unease about safety concerns surrounding its next generation cystic fibrosis drugs, TheStreet's Adam Feuerstein notes.
"However, like most corporate updates offered by Vertex, the good always seems to be tinged with some new risk or concern," he adds.
Separately, TheStreet Ratings team rates the stock as a "hold" with a ratings score of C-.
Vertex's strengths such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth are countered by weaknesses including poor profit margins and a generally disappointing performance in the stock itself.
You can view the full analysis from the report here: VRTX
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.